We demonstrated that genetic and pharmacologic inhibition of DHODH can significantly diminish the proliferation and tumorigenicity of MYCN-amplified neuroblastoma cell lines and slow the progression of established neuroblastoma xenografts. The gene discussed is DHODH; the disease is neuroblastoma.